报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2024年4月24日， 伟思医疗 发布2024年年报及2025年一季报。 伟思医疗成立于2001年，总部位于江苏省南京市，是一家以技术创新驱动的医疗器械公司，也是国家 高新技术企业、科创板上市公司、国家级专精特新"小巨人"企业。公司专注 # 财报数据 公司2024年实现收入 4.00亿 元（同比-13.45%），归母净利润 1.02亿 元（同比-25.16%），扣非归母净 利润 0.83亿 元（同比-31.72%）。 据此计算， 2024Q4单季度实现收入1.08亿元（同比-16.98%）， 归母净利润0.24亿元（同 比-31.16%），扣非归母净利润0.15亿元（同比-51.65%）。 2024年属于医美能量源的塑形磁刺激仪和高频电灼仪两款产品均取得较好的销售成果。同时，导航经颅磁刺 激仪和皮秒激光治疗仪均顺利取证，进一步丰富了公司高端产品矩阵。 2024年拆分 分业务： 磁刺激类收入1.72亿元（同比-13.92%）；电刺激类收入0.37亿元（同比-41.75%）；电生理类收 入0.65亿元（同比+0.25%）；耗材及配件 ...

"躺不平、卷不动"的焦虑蔓延全行业：华兰疫苗遭遇市占率与利润双杀，百克生物的带状疱疹疫苗销售 未达预期，沃森与万泰的HPV价格战两败俱伤……即便严守研发纪律的企业，也难逃估值业绩双杀命 运。 突围三角：技术、矩阵与出海的生死竞速 2024年的中国疫苗行业，正经历一场前所未有的寒冬。A股11家人用疫苗上市公司总市值之和，竟不敌 三年前智飞生物单家峰值；HPV疫苗批签发量暴跌超60%，流感、狂犬等赛道深陷价格战泥潭。当"以 价换量"策略失效、去库存压力高企、回款难题蔓延，这个曾被视为"黄金赛道"的行业，如何在至暗时 刻寻找破晓之光？ 双重绞杀：需求萎缩与价格战的冰火考验 消费端的寒意率先袭来：HPV疫苗全年批签发批次同比锐减61.57%，流感、肺炎疫苗接种量同步下 滑。新生儿数量持续走低，迫使企业将目光转向成人市场，但"消费力不等式"（女人＞小孩＞宠物＞男 人）无情撕开商业幻象——即便万泰生物将HPV疫苗男性适应症获批，市场反响仍显冷淡。 供给端的厮杀更为惨烈：国药集团在流感疫苗市场打响第一枪降价，华兰、科兴被迫跟进；智飞生物在 肺炎疫苗市场祭出"低价换份额"策略，行业毛利率遭腰斩。恶性循环下，8家疫苗企业存货周 ...

Group 1: Company Strategy for 2025 - The company will focus on coconut juice and canned fruit as its two main product pillars while stabilizing existing channels and expanding diversified channels to enhance the product matrix and improve operational efficiency [2][3] - Key areas of work for 2025 include: 1. Continuing channel cultivation and optimizing existing points, with a focus on developing the catering channel and enhancing product visibility [2] 2. Expanding channel diversification and brand promotion, targeting emerging channels like snack specialty chains and emphasizing brand vitality [3] 3. Advancing the dual-driven development strategy for canned fruit and coconut juice, with a structured rollout of coconut water products [3] 4. Implementing the coconut processing project in Vietnam [3] 5. Strengthening supply chain management to improve responsiveness [3] Group 2: Investor Engagement and Feedback - Investors suggested diversifying gifts for shareholders, including coconut water and canned fruit [3] - The company acknowledged the suggestions and expressed gratitude for shareholder engagement [3]

公司公告：拟通过发行股份及支付现金的方式购买东莞市贝特电子科技股份有限公司100%股份。贝特电子产 品主要为电子电路系统的过流和过温保护元器件，24年已实现收入8.26亿元（YoY+31%），净利润1.52亿元 （YoY+44%）。 国信电子观点 1）产品矩阵方面，贝特电子产品对扬杰保护器件产品可进行补充，24年贝特电子已实现收入8.26亿元 （YoY+31%），净利润1.52亿元（YoY+44%），此前在熔断器领域22年全球市占率已超4%；若收购完成，扬 杰在保护器件领域产品矩阵完整度将提升。2）在客户与市场方面，贝特电子与扬杰科技客户重叠度高，产品 方案渐完整有助于公司在头部客户的份额加速做大。3）贝特电子2023年外销占比为26.88%，综合毛利率为 42%，对扬杰毛利率中枢及海外业务均有正向贡献。若本次收购顺利，我们认为对公司产品矩阵、海外布局及 盈利能力均有正向推动；中长期维度，我们看好公司"双品牌"覆盖国内外市场的全球化业务能力，产品与产能 升级的长期规模优势，维持"优于大市"评级。 点击 关注我们 评论 核心观点 事项 贝特电子为国内电力电子保护元件领域的领先企业之一，其产品线涵盖了电子类熔断器 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has established a diversified product matrix with a focus on becoming a leading comprehensive beverage group, enhancing brand value and market competitiveness [6] - The flagship product, Dongpeng Special Drink, has shown steady growth, capturing a 47.9% market share in China's energy drink sector, an increase of 4.9 percentage points year-on-year [6] - The company reported a significant increase in revenue and profit for 2024, with total revenue reaching 15.839 billion yuan, a year-on-year growth of 40.63%, and net profit attributable to shareholders of 3.327 billion yuan, up 63.09% [4] Financial Performance - In 2024, the company achieved a gross margin of 44.81%, an increase of 1.74 percentage points year-on-year, primarily due to lower raw material costs [6] - The net profit margin for 2024 was 21.00%, reflecting a year-on-year increase of 2.89 percentage points [6] - The company’s operating cash flow for 2024 was 5.789 billion yuan, a year-on-year increase of 76.44% [4] Market Position and Growth Strategy - The company is focusing on expanding its product categories, including electrolyte drinks, sugar-free tea, and large-packaged beverages, to optimize its product structure [9] - The second growth curve, "Dongpeng Water," has entered the "billion-level product" category, with a sales volume market share of 6.7%, up 5.0 percentage points year-on-year [6] - The company plans to deepen its national and omnichannel strategies while exploring international markets, including setting up a company in Indonesia to meet local demand for high-quality soft drinks [7] Future Projections - Revenue projections for 2025, 2026, and 2027 are 20.456 billion yuan, 25.393 billion yuan, and 30.189 billion yuan, respectively, with year-on-year growth rates of 29.15%, 24.13%, and 18.89% [9] - Net profit projections for the same years are 4.427 billion yuan, 5.657 billion yuan, and 6.901 billion yuan, with growth rates of 33.06%, 27.80%, and 21.99% [9] - The company is expected to maintain a strong return on equity (ROE) of 40.92% in 2025 [9]